VitalHub Corp. (the “Company” or “VitalHub”) (TSX:VHI)
(OTCQX:VHIBF) announced today it has filed its Interim
Condensed Consolidated Financial Statements and Management's
Discussion and Analysis report for the three and six months ended
June 30, 2024, with the Canadian securities authorities. These
documents may be viewed under the Company’s profile at
www.sedarplus.com.
"We are pleased to report a strong second
quarter in 2024, marked by significant organic growth and strategic
advancements,” stated Dan Matlow, CEO of VitalHub. “With our second
quarter revenue reaching $16.2 million, a 24% increase from the
previous year, and our Adjusted EBITDA(2) rising to $4.2 million, a
41% increase from the previous year, we continue to build on our
strong foundation. Our gross margin remained robust at 81%,
reflecting our ongoing commitment to operational excellence and
cost management. Net income before income taxes increased to $1.4
million, an 86% increase from the previous year. This quarter also
saw our Annual Recurring Revenue (ARR)(1-2) grow to $51.3 million,
up 25% year-over-year, which underscores the robustness of our
business model and the scalability of our solutions. We concluded
the quarter with a solid cash position of $71.6 million, enabling
us to pursue both organic growth and strategic acquisitions
effectively. Subsequent to the quarter's end, we announced a
definitive agreement to acquire MedCurrent Corporation
(“MedCurrent”), a leader in Clinical Decision Support. This
acquisition is a testament to our commitment to integrating
cutting-edge technology solutions that enhance healthcare delivery
and support our strategic expansion. MedCurrent's innovative
platform, OrderWise, which leverages artificial intelligence to
optimize clinical decisions at the point of care, aligns perfectly
with our aim to reduce healthcare costs and improve patient
outcomes.”
“Looking ahead, VitalHub has created a solid
platform on which we can continue to build. Our strategy of
operational excellence, coupled with disciplined cash management,
positions us well to capitalize on emerging opportunities and
navigate future challenges in the healthcare technology sector. We
are excited about our future prospects and remain committed to
driving innovation, enhancing customer value, and expanding our
market leadership."
VitalHub Corp’s quarterly investor
conference call will take place on Friday, August 9, 2024, at
9:00AM EST.
To register for the call, please
visit:
https://us02web.zoom.us/webinar/register/WN_-Es4D85lTaCMdHGDz9A15w
Second Quarter 2024
Highlights
- Revenue of $16,237,605 as compared to $13,085,441 in the
equivalent prior year period, an increase of $3,152,164 or
24%.
- Gross profit as a percentage of revenue was 81% compared to 81%
in the equivalent prior year period.
- Gross profit as a percentage of revenue remained consistent due
to an ongoing effort to manage costs and gain operating cost
synergies.
- ARR ⁽¹⁻²⁾ at June 30, 2024 was $51,283,570 as compared to
$47,834,002 at March 31, 2024, an increase of $3,449,568 or 7%.
- ARR ⁽¹⁻²⁾ growth was due to organic growth of $1,239,568 or 3%,
and acquisition growth of $2,249,000 or 5% and a loss of $39,000 or
0% due to the fluctuations in foreign exchange rates during the
quarter.
- Net income before income taxes of $1,383,605 as compared to net
income before income taxes of $742,516 in the equivalent prior year
period, an increase of $641,089 or 86%.
- The increase was primarily attributable to the increase in
revenues from organic growth and acquisitions, coupled with an
ongoing effort to manage costs and gain operating cost
synergies.
- EBITDA ⁽²⁾ of $1,972,452 compared to $1,979,464 in the
equivalent prior year period, a decrease of $7,012.
- Adjusted EBITDA ⁽²⁾ of $4,193,985 or 26% of revenue, compared
to $2,970,322 or 23% of revenue in the equivalent prior year
period, an increase of $1,223,663 or 41%.
- The increase in Adjusted EBITDA from Q2 2023 to Q2 2024 was
primarily attributable to the higher recurring revenues of
$13,039,369 in Q2 2024, as compared to $10,210,645 in Q2 2023,
coupled with an ongoing effort to manage costs and gain operating
cost synergies.
- On June 7, 2024, the Company acquired all of the issued and
outstanding shares of Premier I.T. Partnership Limited (“Premier”)
for total consideration of $5,349,327 CAD. Premier is a UK-based
company, which offers market-leading workforce planning,
development and performance solutions for the healthcare
sector.
Six Month 2024 Highlights
- Revenue of $31,494,396 as compared to $25,680,615 in the
equivalent prior year period, an increase of $5,813,781 or
23%.
- Gross profit as a percentage of revenue was 81% compared to 81%
in the equivalent prior year period.
- Gross profit as a percentage of revenue remained consistent due
to an ongoing effort to manage costs and gain operating cost
synergies.
- ARR ⁽¹⁻²⁾ at June 30, 2024 was $51,283,570 as compared to
$41,008,702 at June 30, 2023, an increase of $10,274,868 or 25%.
- ARR ⁽¹⁻²⁾ growth was primarily due to organic growth of
$6,221,042 or 16%, acquisition growth of $3,311,500 or 8%, and a
gain of $742,326 or 2% due to the increase in GBP rates relative to
the CAD dollar.
- Net income before income taxes of $3,362,500 as compared to net
income before income taxes of $1,522,944 in the equivalent prior
year period, an increase of $1,839,556 or 121%.
- The increase was primarily attributable to the increase in
revenues from organic growth and acquisitions, coupled with an
ongoing effort to manage costs and gain operating cost
synergies.
- EBITDA ⁽²⁾ of $5,071,468 compared to $3,967,211 in the
equivalent prior year period, an increase of $1,104,257 or
28%.
- Adjusted EBITDA ⁽²⁾ of $8,238,917 or 26% of revenue, compared
to $5,894,102 or 23% of revenue in the equivalent prior year
period, an increase of $2,344,815 or 41%.
- The increase in Adjusted EBITDA from Q2 2023 to Q2 2024 was
primarily attributable to the higher recurring revenues of
$13,039,369 in Q2 2024, as compared to $10,210,645 in Q2 2023,
coupled with an ongoing effort to manage costs and gain operating
cost synergies.
- Cash on hand at June 30, 2024 was $71,570,488 compared to
$33,480,018 as at December 31, 2023.
- The increase is primarily due to a bought deal offering of
approximately $37 million in net proceeds, plus cash generated from
operations.
- Cash from operations before changes in working capital was
$5,125,317 as compared to $4,068,458 for the same period last
year.
- During the quarter, the Company closed a bought deal offering
for total gross proceeds of approximately $40,254,000.
- On April 9, 2024, the Company closed a bought deal public
offering with a syndicate of investment dealers led by Cormark
Securities Inc. (collectively, the “underwriters”) pursuant to
which the underwriters purchased 6,709,000 common shares (the
"common shares") from the treasury of the Company, at a price of
$6.00 per common share for total gross proceeds of approximately
$40,254,000.
(1) The Company defines annual recurring revenue
(“ARR”) as the recurring revenue expected based on yearly
subscriptions of the renewable software license fees and
maintenance services.(2) Non-IFRS measure.
SELECTED FINANCIAL INFORMATION |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended |
Six months ended |
|
June 30, 2024 |
% Revenue |
June 30, 2023 |
% Revenue |
Change |
June 30, 2024 |
% Revenue |
June 30, 2023 |
% Revenue |
Change |
|
$ |
|
$ |
|
% |
$ |
|
$ |
|
% |
Revenue |
16,237,605 |
100% |
13,085,441 |
100% |
24% |
31,494,396 |
100% |
25,680,615 |
100% |
23% |
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
3,068,801 |
19% |
2,468,871 |
19% |
(24%) |
6,042,493 |
19% |
4,940,748 |
19% |
(22%) |
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
13,168,804 |
81% |
10,616,570 |
81% |
24% |
25,451,903 |
81% |
20,739,867 |
81% |
23% |
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
General and administrative |
3,260,964 |
20% |
2,558,469 |
20% |
(27%) |
6,452,821 |
20% |
6,169,561 |
24% |
(5%) |
Sales and marketing |
1,821,834 |
11% |
1,739,979 |
13% |
(5%) |
3,518,298 |
11% |
3,021,644 |
12% |
(16%) |
Research and development |
3,675,359 |
23% |
3,293,624 |
25% |
(12%) |
7,093,481 |
23% |
5,813,645 |
23% |
(22%) |
Depreciation of property and equipment |
81,174 |
0% |
82,885 |
1% |
2% |
159,004 |
1% |
158,168 |
1% |
(1%) |
Depreciation of right-of-use assets |
111,245 |
1% |
101,742 |
1% |
(9%) |
218,007 |
1% |
197,649 |
1% |
(10%) |
Share-based compensation |
675,674 |
4% |
293,957 |
2% |
(130%) |
1,024,253 |
3% |
571,641 |
2% |
(79%) |
Deferred share-based compensation |
0 |
0% |
97,560 |
1% |
0% |
0 |
0% |
97,560 |
0% |
100% |
Foreign currency loss (gain) |
216,662 |
1% |
54,176 |
0% |
(300%) |
148,386 |
0% |
(159,085) |
(1%) |
193% |
|
|
|
|
|
|
|
|
|
|
|
Other income and expenses |
|
|
|
|
|
|
|
|
|
|
Amortization of intangible assets |
1,114,299 |
7% |
1,070,214 |
8% |
(4%) |
2,220,841 |
7% |
2,124,461 |
8% |
(5%) |
Business acquisition, restructuring and integration costs |
1,199,964 |
7% |
353,016 |
3% |
(240%) |
1,797,301 |
6% |
1,011,365 |
4% |
(78%) |
Loss on change in fair value of contingent consideration |
345,895 |
2% |
246,325 |
2% |
(40%) |
345,895 |
1% |
246,325 |
1% |
(40%) |
Interest expense and accretion (net of interest income) |
(729,595) |
(4%) |
(37,368) |
(0%) |
1852% |
(914,402) |
(3%) |
(76,355) |
(0%) |
(1098%) |
Interest expense from lease liabilities |
11,724 |
0% |
19,475 |
0% |
40% |
25,518 |
0% |
40,344 |
0% |
37% |
|
|
|
|
|
|
|
|
|
|
|
Current and deferred income taxes |
1,718,658 |
11% |
121,065 |
1% |
(1320%) |
2,379,087 |
8% |
739,325 |
3% |
(222%) |
|
|
|
|
|
|
|
|
|
|
|
Net income |
(335,053) |
(2%) |
621,451 |
5% |
(154%) |
983,413 |
3% |
783,619 |
3% |
25% |
|
|
|
|
|
|
|
|
|
|
|
EBITDA(Non-IFRS measure) |
1,972,452 |
12% |
1,979,464 |
15% |
(0%) |
5,071,468 |
16% |
3,967,211 |
15% |
28% |
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA(Non-IFRS
measure) |
4,193,985 |
26% |
2,970,322 |
23% |
41% |
8,238,917 |
26% |
5,894,102 |
23% |
40% |
|
|
|
|
|
|
|
|
|
|
|
Annual recurring revenue(Non-IFRS
measure) |
51,283,570 |
|
41,008,702 |
|
25% |
51,283,570 |
|
41,008,702 |
|
25% |
|
|
|
|
|
|
|
|
|
|
|
Term licences, maintenance and support
revenue |
13,039,369 |
80% |
10,210,645 |
78% |
28% |
25,504,431 |
81% |
20,208,129 |
79% |
26% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As at |
|
|
|
|
|
|
|
|
|
June 30, 2024 |
December 31, 2023 |
|
|
|
|
|
|
|
|
|
$ |
$ |
|
|
|
|
|
|
Deferred revenue |
|
31,678,227 |
21,049,975 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash balance |
|
|
71,570,488 |
33,480,018 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ABOUT VITALHUB
Software for Health and Human Services providers
designed to simplify the user experience and optimize outcomes.
VitalHub is a leading software company dedicated
to empowering Health and Human Services providers. Our clients
include hospitals, regional health authorities, mental health and
addictions services providers for children and adults, long-term
care facilities, home health agencies, correctional services, and
community and social services providers.
VitalHub’s comprehensive suite of SaaS solutions
include:
- Electronic Health Record (EHR),
Case Management, Care Coordination, and Optimization
- Patient Flow, Operational
Visibility, and Patient Journey Optimization
- Workforce Automation
The Company has a robust two-pronged growth
strategy, targeting organic growth opportunities within its product
suite, and pursuing an aggressive M&A plan. Currently VitalHub
serves more than 1,000 clients across Canada, USA, UK, Australia,
the Middle East, and Europe.
VitalHub is based in Toronto, Canada, with an
offshore development hub in Sri Lanka. The VitalHub team comprises
more than 400 team members globally. The Company is publicly traded
on the Toronto Stock Exchange (TSX) under the symbol "VHI" and on
the OTC Markets OTCQX Exchange under the symbol "VHIBF".
https://www.vitalhub.com/
CAUTIONARY STATEMENT
Certain statements contained in this news
release may constitute "forward-looking information" or "financial
outlook" within the meaning of applicable securities laws that
involve known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking
information or financial outlook. Often, but not always,
forward-looking statements can be identified by the use of words
such as "plans", "is expected", "expects", "scheduled", "intends",
"contemplates", "anticipates", "believes", "proposes" or variations
(including negative variations) of such words and phrases, or state
that certain actions, events or results "may", "could", "would",
"might" or "will" be taken, occur or be achieved. Such statements
are based on the current expectations of the management of each
entity and are based on assumptions and subject to risks and
uncertainties. Although the management of each entity believes that
the assumptions underlying these statements are reasonable, they
may prove to be incorrect. Although the Company has attempted to
identify important factors that could cause actual actions, events
or results to differ materially from those described in
forward-looking statements, there may be other factors that cause
actions, events or results to differ from those anticipated,
estimated or intended. No forward-looking statement can be
guaranteed. Except as required by applicable securities laws,
forward-looking statements speak only as of the date on which they
are made and the Company undertakes no obligation to publicly
update or revise any forward-looking statement, whether as a result
of new information, future events, or otherwise.
CONTACT INFORMATION
Dan MatlowChief Executive Officer, Director(416)
727-9061dan.matlow@VitalHub.com
Vitalhub (TSX:VHI)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Vitalhub (TSX:VHI)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024